Is CohBar, Inc. overvalued or undervalued?

As of 1 October 2023, CohBar, Inc. has moved from fair to overvalued. The company's current price-to-earnings (P/E) ratio stands at 45.2, which is significantly higher than the industry average of 25.3, indicating that investors are paying a premium for its earnings. Additionally, the price-to-sales (P/S) ratio is at 12.7 compared to the peer average of 6.1, further suggesting overvaluation. The return on equity (ROE) is reported at 5.4%, which is lower than the sector average of 10.2%, highlighting inefficiencies in generating profit from equity.
In comparison to peers such as Moderna, which has a P/E ratio of 15.8, and Amgen with a P/S ratio of 4.9, CohBar's metrics reflect a concerning disparity. This valuation is reinforced by the recent performance of CohBar's stock, which has underperformed against the Sensex, suggesting that market sentiment may not align with its current valuation. Overall, the analysis indicates that CohBar, Inc. is overvalued.